872998-61-3 Usage
General Description
2,4-DIBROMOQUINAZOLINE is a chemical compound that consists of a quinazoline ring with two bromine atoms attached at the 2 and 4 positions. It is a white to light tan solid with a molecular formula of C9H5Br2N2. 2,4-DIBROMOQUINAZOLINE is used as an intermediate in the synthesis of various organic compounds, such as pharmaceuticals, agrochemicals, and dyes. It has been studied for its potential use as a chemical building block for designing new materials and has demonstrated biological activity in some research studies. Additionally, 2,4-DIBROMOQUINAZOLINE may pose potential health and environmental risks, and proper safety precautions should be followed when handling and using this chemical.
Check Digit Verification of cas no
The CAS Registry Mumber 872998-61-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,7,2,9,9 and 8 respectively; the second part has 2 digits, 6 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 872998-61:
(8*8)+(7*7)+(6*2)+(5*9)+(4*9)+(3*8)+(2*6)+(1*1)=243
243 % 10 = 3
So 872998-61-3 is a valid CAS Registry Number.
InChI:InChI=1/C8H4Br2N2/c9-7-5-3-1-2-4-6(5)11-8(10)12-7/h1-4H
872998-61-3Relevant articles and documents
Evaluation of quinazoline analogues as glucocerebrosidase inhibitors with chaperone activity
Marugan, Juan J.,Zheng, Wei,Motabar, Omid,Southall, Noel,Goldin, Ehud,Westbroek, Wendy,Stubblefield, Barbara K.,Sidransky, Ellen,Aungst, Ronald A.,Lea, Wendy A.,Simeonov, Anton,Leister, William,Austin, Christopher P.
experimental part, p. 1033 - 1058 (2011/04/25)
Gaucher disease is a lysosomal storage disorder (LSD) caused by deficiency in the enzyme glucocerebrosidase (GC). Small molecule chaperones of protein folding and translocation have been proposed as a promising therapeutic approach to this LSD. Most small molecule chaperones described in the literature contain an iminosugar scaffold. Here we present the discovery and evaluation of a new series of GC inhibitors with a quinazoline core. We demonstrate that this series can improve the translocation of GC to the lysosome in patient-derived cells. To optimize this chemical series, systematic synthetic modifications were performed and the SAR was evaluated and compared using three different readouts of compound activity: enzymatic inhibition, enzyme thermostabilization, and lysosomal translocation of GC.
